Kaltsa G, Bamias G, Siakavellas SI, Goukos D, Karagiannakis D, Zampeli E, Vlachogiannakos J, Michopoulos S, Vafiadi I, Daikos GL, et al. Systemic levels of human $\beta$-defensin 1 are elevated in patients with cirrhosis. Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology. 2016;29:63.

Koskinas J, Deutsch M, Ioannidou P, Manolakopoulos S, Cholongitas E, Rigopoulou EI, Schina MJ, Sevastianos VA, Elefsiniotis LS, Goulis J, et al. Efficacy and safety of direct acting antiviral (s)(DAA) containing regimens in the treatment of chronic hepatitis C (CHC) patients with genotype 3. A real life experience. In: Hepatology. Vol. 63. WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2016. pp. 1007A–1008A.

Vlachogiannakos J, Kapatais A, Elefsiniotis IS, Koskinas J, Papageorgiou M-V, Manolakopoulos S, Gatselis N, Cholongitas E, Deutsch M, Karatapanis S, et al. Efficacy and safety of ombitasvir (OBV) and ritonavir boosted paritaprevir (PRV/r) with or without dasabuvir (DSV) regimens in genotype 1 or 4 HCV infected patients. A Greek multicenter real-life cohort study. In: HEPATOLOGY. Vol. 64. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2016. pp. 998A–998A.

Elefsiniotis LS, Dalekos GN, Koskinas J, Ioannidou P, Cholongitas E, Manolakopoulos S, Goulis J, Vlachogiannakos J, Deutsch M, Triantos CK, et al. Daclatasvir (DCV) plus Sofosbuvir (SOF) regimens in chronic Hepatitis C Virus (HCV) infected patients with advanced fibrosis or cirrhosis. In: HEPATOLOGY. Vol. 64. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2016. pp. 990A–991A.

Varbobitis IC, Siakavellas SI, Koutsounas IS, Karagiannakis DS, Ioannidou P, Papageorgiou M-V, Pavlopoulou ID, Schizas D, Bamias G, Vlachogiannakos I, et al. Reliability and applicability of two-dimensional shear-wave elastography for the evaluation of liver stiffness. European journal of gastroenterology & hepatology. 2016;28:1204–1209.

Sinakos E, Ketikoglou I, Koskinas J, Kapatais A, Ioannidou P, Goulis J, Manolakopoulos S, Manesis EK, Vlachogiannakos J, Deutsch M, et al. Safety and efficacy of regimens including direct acting antivirals (DAAs) in chronic hepatitis C (CHC) patients over the age of 70 years. In: HEPATOLOGY. Vol. 64. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2016. pp. 983A–984A.

Papatheodoridis GV, Kapatais A, Goulis I, Elefsiniotis IS, Vlachogiannakos J, Manolakopoulos S, Dalekos GN, Koskinas J, Karatapanis S, Ketikoglou I, et al. Efficacy and safety of the currently recommended regimens with direct acting antiviral (s)(DAA) in the treatment of chronic hepatitis C (CHC) patients in clinical practice. A Greek multicenter real-life cohort study. In: HEPATOLOGY. Vol. 64. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2016. pp. 977A–977A.